DOI: https://dx.doi.org/10.18203/2394-6040.ijcmph20222967
Published: 2022-11-28

Prescribing patterns of systemic antifungal medications in Indian patients with invasive fungal infections: a multicenter retrospective study

Lav Patel, Shreekant Sharma, Deepak Bunger

Abstract


Background: Objectives of the study was to describe the utilization pattern of systemic antifungal agents in Indian patients with invasive fungal infections (IFIs).

Methods: This real-world, multicenter (127 centers), retrospective analysis included data of patients receiving systemic antifungal medications at various centers across India. The study data was collected between April 2021 and March 2022.

Results: Data of a total of 323 patients was analyzed. The mean age of patients was 54┬▒13.52 years. There was male preponderance seen in this study (72.4%). Diabetes was the most common comorbidity (36.8%) followed by concomitant diabetes and hypertension (31.9%), hypertension (9.6%) and hematological malignancies (9.6%). The most common indication occurring in >10% of the patients and for whom systemic antifungals were used included pulmonary mucormycosis (33.1%) followed by invasive candidiasis (16.1%), sepsis (13.3%) and fungal pneumonia (11.8%). In total 323 patients, the most common antifungal drug prescribed was posaconazole (38.6%) followed by anidulafungin (32.8%), caspofungin (10.5%), fluconazole (9.3%) and micafungin (8.7%). Posaconazole was most commonly used for pulmonary mucormycosis (84.8%), fluconazole for sepsis (33.3%), caspofungin for fungal pneumonia (23.5%) and anidulafungin (33.1%), and micafungin (39.3%) for invasive candidiasis.

Conclusions: This study provides real-world evidence on the demographics of Indian patients with IFIs and utilization pattern of systemic antifungals by health care physicians in clinical practice.


Keywords


Antifungal, Mucormycosis, Candida, Posaconazole, Caspofungin

Full Text:

PDF

References


McKeny PT, Nessel TA, Zito PM. Antifungal Antibiotics. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2022 Jan-. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538168/. Accessed on 2022 Aug 25.

Chakrabarti A, Chatterjee SS, Shivaprakash MR. Overview of opportunistic fungal infections in India. Nihon Ishinkin Gakkai Zasshi. 2008;49:165-72.

Sable CA, Strohmaier KM, Chodakewitz JA. Advances in antifungal therapy. Annu Rev Med. 2008;59:361-79.

Singh T, Kashyap AK, Ahluwalia G, Chinna D, Sidhu SS. Epidemiology of fungal infections in critical care setting of a tertiary care teaching hospital in North India: a prospective surveillance study. Mortality. 2014;1:19-25.

Gupta A, Sharma A, Chakrabarti A. The emergence of post-COVID-19 mucormycosis in India: Can we prevent it? Indian J Ophthalmol. 2021;69:1645-7.

Al Balushi KA, Alzaabi MA, Alghafri F. Prescribing Pattern of Antifungal Medications at a Tertiary Care Hospital in Oman. J Clin Diagn Res. 2016;10:Fc27-30.

Allen U. Antifungal agents for the treatment of systemic fungal infections in children. Paediatr Child Health. 2010;15:603-15.

Ghannoum MA, Rice LB. Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev. 1999;12:501-17.

Kongkookum A, Rattanachotphanit T, Limwattananon C. Prescribing Pattern of Antifungal Agents for Superficial Fungal Infection at a District Hospital. Isan J Pharmaceutical Sci. 2017;13:39-49.

Bansal P, Baishnab S, Singla A. Drug prescribing pattern of antifungal drugs for local fungal infections in a tertiary care hospital: MAMC, Agroha. Bansal P, Baishnab S, Singla A. Drug prescribing pattern of antifungal drugs for local fungal infections in a tertiary care hospital: MAMC, Agroha. 202;2021;10:5.

Ghanem M, Zein A, Makhlouf H, Farghaly S, ElGezawy E, Mohrram A. Role of Comorbidities in Acquiring Pulmonary Fungal Infection in COPD Patients. Chest. 2016;150:915A.

Cornely OA, Arikan-Akdagli S, Dannaoui E, Groll AH, Lagrou K, Chakrabarti A et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(3):5-26.

DUPIXENT® (dupilumab) injection, for subcutaneous use. Prescribing Information. Revised September, 2022. Available at: https://www. accessdata.fda.gov/drugsatfda_docs/label/2022/761055s044lbl.pdf. Accessed on October 12, 2022.

Demir KK, Butler-Laporte G, Del Corpo O, Ekmekjian T, Sheppard DC, Lee TC et al. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis. Mycoses. 2021;64:1098-110.

Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;62:e1-50.

Wang ES. Guideline recommendations for the prophylaxis of invasive aspergillosis in AML. Clin Adv Hematol Oncol. 2016;14:876-9.

Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G et al. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol. 2014;93:13-32.